Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Sponsor: CSL Behring
Summary
This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigilimab in participants with SCD. Participants will be treated for 64 weeks: for 12 weeks in the dose escalation period, where the dose will be escalated to each participant's individual MTD; and for 52 weeks at the MTD in the maintenance period.
Official title: Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
63
Start Date
2026-02-02
Completion Date
2028-06-29
Last Updated
2026-02-20
Healthy Volunteers
No
Conditions
Interventions
Anumigilimab
Participants will receive anumigilimab, escalated to a maximum dose guided by absolute neutrophil count (ANC) and safety concerns.
Placebo
Volume matched saline will be administered SC.
Locations (3)
The Foundation for Sickle Cell Disease
Hollywood, Florida, United States
Southern Specialty Research
Flowood, Mississippi, United States
Jacobi Medical Center
The Bronx, New York, United States